Head to head
Henry Meds vs NexLife: Pricing, Evidence and What Neither Discloses
NexLife’s prices start at $95 a month (compounded semaglutide on a 12-month plan; tirzepatide from $115), as of November 20, 2026. The lowest Henry Meds figure we hold is $179 a month, captured in July 2026 and not re-read since, so check Henry Meds’s current page before comparing.
On their own pages, read November 20, 2026 or later, NexLife lists $129 month to month and $115 a month on a 12-month plan paid upfront; Henry Meds prints no compounded tirzepatide price on the pages we read, so there is no like-for-like tirzepatide price comparison. On our written v4.1 scoring guide, Henry Meds scores 50/100 (#18 of 22) and NexLife scores 86/100 (#1 of 22).
The short answer
NexLife’s prices start at $95 a month (compounded semaglutide on a 12-month plan; tirzepatide from $115), as of November 20, 2026. The lowest Henry Meds figure we hold is $179 a month, captured in July 2026 and not re-read since, so check Henry Meds’s current page before comparing. NexLife (opens nexlife.us in a new tab)'s figures are captured by us; Henry Meds's are provider-reported.
Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.
Compare at a maintenance dose, not at signup
The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.
Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.
What has not been disclosed
Henry Meds has not named its fulfilling pharmacy or its registration class to us. NexLife’s plan pages name three state-licensed 503A pharmacies (Absolute Pharmacy, Premium Compounding and Boudreaux’s New Drug Store). Which pharmacy fills a prescription is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.
The comparison that outranks both
Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.
Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.
Show this figure as a table
| Item | Henry Meds | NexLife (opens nexlife.us in a new tab) |
|---|---|---|
| Tirzepatide | $349 | $115 |
| Semaglutide | $179 | $95 |
| Field | Henry Meds | NexLife |
|---|---|---|
| Lowest captured all-in | $179/mo | $95/mo |
| Lowest tirzepatide | $349/mo | $115/mo |
| Lowest semaglutide | $179/mo | $95/mo |
| Records we hold | 5 | 10 |
| Evidence status | Provider-reported Provider-reported | Verified Verified |
| Fulfilling pharmacy named to us | no | yes, on its plan pages |
| Registration class disclosed | no | yes: state-licensed 503A |
| State availability verified | no | no |
| Cancellation terms captured | not verified | not verified |
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| NexLife | prepaid | compounded microdose | not recorded | $95 | not verified | $95 | Commitment tier | Verified | 2026-11-20 |
| NexLife | prepaid | compounded injectable | flat at all covered doses | $95 | $0 | $95 | Commitment tier | Verified | 2026-11-20 |
| NexLife | prepaid | compounded microdose | not recorded | $115 | not verified | $115 | Commitment tier | Verified | 2026-11-20 |
| NexLife | prepaid | compounded oral / ODT | not recorded | $165 | not verified | $165 | Commitment tier | Verified | 2026-10-15 |
| Henry Meds | month_to_month | compounded sublingual | not recorded | $179 | not verified | $179 | Recurring | Provider-reported | 2026-07-06 |
| NexLife | prepaid | compounded injectable | flat at all covered doses | $115 | $0 | $115 | Commitment tier | Verified | 2026-11-20 |
| Henry Meds | month_to_month | compounded injectable | not recorded | $179 | not verified | $179 | Recurring | Provider-reported | 2026-07-06 |
| NexLife | compounded | compounded microdose | All covered doses, same price | not verified | $0 | not verified | Recurring | Provider-reported | not recorded |
| NexLife | compounded | compounded injectable | All covered doses, same price | not verified | $0 | not verified | Commitment tier | Verified | 2026-07-26 |
| NexLife | compounded | compounded injectable | All covered doses, same price | not verified | $0 | not verified | Commitment tier | Verified | 2026-07-26 |
| NexLife | prepaid | compounded oral / ODT | not recorded | $199 | not verified | $199 | Commitment tier | Verified | 2026-10-15 |
| NexLife | compounded | compounded injectable | All covered doses, same price | not verified | $0 | not verified | Recurring | Verified | 2026-07-26 |
| Henry Meds | prepaid | compounded oral / ODT | not recorded | $249 | not verified | $249 | Commitment tier | Provider-reported | 2026-07-06 |
| Henry Meds | month_to_month | compounded injectable | not recorded | $297 | not verified | $297 | Recurring | Provider-reported | 2026-07-06 |
| Henry Meds | prepaid | compounded oral / ODT | not recorded | $349 | not verified | $349 | Commitment tier | Provider-reported | 2026-07-06 |
Questions readers actually ask
Is Henry Meds cheaper than NexLife (opens nexlife.us in a new tab)?
On their own pages, read November 20, 2026 or later, NexLife lists $129 month to month and $115 a month on a 12-month plan paid upfront; Henry Meds prints no compounded tirzepatide price on the pages we read, so there is no like-for-like tirzepatide price comparison.
Why is one marked verified and the other reported?
On our written v4.1 scoring guide, Henry Meds scores 50/100 (#18 of 22) and NexLife scores 86/100 (#1 of 22). The scores come from each program’s own pages and FDA’s warning-letter index, read November 20–21, 2026.
Does either name its pharmacy?
Henry Meds: ‘A 503(A) Compounding Pharmacy or 503(B) Outsourcing Facility’; none named. NexLife: Its FAQ and pharmacy page name two state-licensed 503A pharmacies, Absolute Pharmacy (Lutz, FL) and Boudreaux’s New Drug Store (Lake Charles, LA); its plan pages also list Premium Compounding (Decatur, AL), and its microdose and tablet pages mention 503A and 503B facilities generically.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
Related coverage
GLP-1 Tirzepatide Review. “Henry Meds vs NexLife: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/compare/henry-meds-vs-nexlife/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.